日期 | 股东名称 | 披露原因 | 买入/卖出涉及 的股份数目 |
每股平均价 | 持有权益的 股份数目 |
占已发行 股本(%) |
31/01/2025 | UBS Group AG | 1306(L) | 913,990(L) | 527,485,901(L) 509,942,221(S) | 14.02 13.56 | |
27/01/2025 | UBS Group AG | 1402(S) | +23,360,060(S) | 549,884,399(L) 511,288,719(S) | 14.62 13.59 | |
23/01/2025 | UBS Group AG | 1502(S) | -2,286,500(S) | 544,339,794(L) 487,864,533(S) | 14.47 12.97 | |
21/01/2025 | UBS Group AG | 1703(L) 1402(S) | +5,424,000(L) +5,424,000(S) | 529,997,260(L) 494,332,581(S) | 14.09 13.14 | |
17/01/2025 | UBS Group AG | 1306(L) | 68,401,173(L) | 517,535,765(L) 487,098,765(S) | 13.76 12.95 | |
10/01/2025 | Luye Life Sciences Group Ltd | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Ginkgo (PTC) Limited | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | LuYe Pharmaceutical International Co., Ltd. | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Ginkgo (PTC) Limited | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Nelumbo Investments Limited | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | UBS Group AG | 1703(L) 1402(S) | +74,000,500(L) +37,000,000(S) | 505,171,643(L) 477,583,143(S) | 13.43 12.70 | |
10/01/2025 | Shorea LBG | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Luye Pharma Holdings Ltd. | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | LuYe Pharmaceutical Investment Co., Ltd. | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Shorea LBG | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | 刘殿波 | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Nelumbo Investments Limited | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Luye Life Sciences Group Ltd | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | LuYe Pharmaceutical International Co., Ltd. | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Luye Pharma Holdings Ltd. | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Luye Pharma Holdings Ltd. | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Luye Pharma Holdings Ltd. | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Luye Life Sciences Group Ltd | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | LuYe Pharmaceutical Investment Co., Ltd. | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | LuYe Pharmaceutical International Co., Ltd. | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Ginkgo (PTC) Limited | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Shorea LBG | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | LuYe Pharmaceutical Investment Co., Ltd. | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | LuYe Pharmaceutical International Co., Ltd. | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | 刘殿波 | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | 刘殿波 | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | 刘殿波 | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | Ginkgo (PTC) Limited | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Shorea LBG | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Luye Life Sciences Group Ltd | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
10/01/2025 | LuYe Pharmaceutical Investment Co., Ltd. | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Nelumbo Investments Limited | 14015(S) | +37,000,000(S) | 1,261,196,703(L) 237,861,950(S) | 33.53 6.32 | |
10/01/2025 | Nelumbo Investments Limited | 1313(L) | 37,000,000(L) | 1,261,196,703(L) 229,317,950(S) | 33.53 6.10 | |
07/01/2025 | UBS Group AG | 1213(L) 1402(S) | -9,886,500(L) +92,028,711(S) | 443,106,171(L) 449,660,971(S) | 11.78 11.95 | |
03/01/2025 | UBS Group AG | 1305(L) | 68,623,827(L) | 456,292,400(L) 360,935,000(S) | 12.13 9.60 | |
1 2 3 4 5 |
备注: | (L) - 长仓:包括 (1) 持有股份;(2) 透过持有丶沽出或发行金融合约,有权或有责任购买相关股份。 |
(S) - 短仓:包括 (1) 借入股份;(2) 透过持有丶沽出或发行金融合约,有权或有责任沽出相关股份。 | |
(P) - 可供借出的股份 | |
即时报价更新时间为 11/02/2025 18:00 | |
港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |